Concepedia

Phase II study of bevacizumab and temsirolimus combination therapy for recurrent glioblastoma multiforme.

Ulrik Lassen, Morten Mau‐Sørensen, Tine Bernhardtsen Gaziel, Benedikte Hasselbalch, Hans Skovgaard Poulsen

PubMed · 2013 · 96 citations · 13 references

Abstract

Temsirolimus can be safely administered in combination with bevacizumab. This study failed to detect activity of such a combination in patients with progressive GBM beyond bevacizumab therapy.

References

13

mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt

Kathryn O’Reilly, F. Rojo, Qing‐Bai She et al. · Cancer Research · 2006 · 2.5K citations · Full text

Randomized Phase II Study of Multiple Dose Levels of CCI-779, a Novel Mammalian Target of Rapamycin Kinase Inhibitor, in Patients With Advanced Refractory Renal Cell Carcinoma

Michael B. Atkins, Manuel Hidalgo, Walter M. Stadler et al. · Journal of Clinical Oncology · 2004 · 943 citations · Full text

, , +15

Phase II Trial of Temsirolimus (CCI-779) in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study

Evanthia Galanis, Jan C. Buckner, Matthew J. Maurer et al. · Journal of Clinical Oncology · 2005 · 690 citations · Full text

Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme

Susan M. Chang, Patrick Y. Wen, Timothy F. Cloughesy et al. · Investigational New Drugs · 2005 · 400 citations · Full text

, , +9

mTOR Inhibitor RAD001 (Everolimus) Has Antiangiogenic/Vascular Properties Distinct from a VEGFR Tyrosine Kinase Inhibitor

Heidi A. Lane, Jeanette M. Wood, Paul M.J. McSheehy et al. · Clinical Cancer Research · 2009 · 250 citations · Full text